ESTRO 36 Abstract Book

S616 ESTRO 36 2017 _______________________________________________________________________________________________

A. Vila 1 , J. Perez de Olaguer 1 , P. Gallego 1 , G. Carrera 1 , A. Pedro 1 1 Platón Hospital, Oncology and Radiation therapy, Barcelona, Spain Purpose or Objective To analyse the quality of life in stage I-III breast cancer patients under systemic treatment versus in adjuvant radiotherapy respect a control group, to observe and to assess priorities regarding quality of life Material and Methods Between May and July of 2014, n: 90 EORTC QLQ C-30 global tests were retrospectively observed in 48 women divided in 3 groups: A) Sixteen breast cancer patients under systemic treatment (following adjuvant chemotherapy or hormonal treatment). B) Sixteen breast cancer patients following radiotherapy were scored at the beginning, during radiotherapy and when radiotherapy courses just ended. C) Sixteen women, hospital workers, without cancer control group, which two were finally refused because they had symptoms of chronic fatigue Results Women mean ages were 63.5 years old (A), 60.5 years old (B) and 41 years old in group C, respectively. Among those 32 breast cancer patient (n: 76 tests), 6 (19%) were submitted to mastectomy and 26 (81%) to conservative surgery, with 5 of them that had been treated with neo - adjuvant chemotherapy. Breast cancer (TNM) stage was I, II or III in 50%, 37.5% and 12.5%, respectively. Asthenia was the main symptom in all cases being low in control group. However, asthenia was considerable or severe in the 56% of cases in the systemic treatment group and 27.5% in radiotherapy group. Asthenia increases a 6% just after radiotherapy. Apart of asthenia, by groups; A) they showed weakness (87.5%) and anorexia (70%) in relation with cytotoxic effects, and 50% in this group of patients showed considerable to severe depression feeling. B) Pain (50%), generally caused by the set-up position and the skin effects of radiotherapy, and 31% of this group of patients showed considerable to severe depression feeling. C) Low degrees of Insomnia, constipation and mild depression were also present in this group. It was found relationship between high degrees of fatigue and females older than 45 years old, tumour poor differentiation, advanced II-III stage, and hormonal treatment when they were tested. In second term PS, several skeleton bone or articular diseases. The presence of mastectomy and thyroidal diseases were frequent in the worst answer tests. Also depression status is determinant in prognosis, but none common profile or clear relationship between high degrees of fatigue and biological factors as ki67, P-53, hormonal receptors, perineural affection, C-her2neu/FISH, tumoral markers as CA 15.3 were found Conclusion 1. Quality of live and treatment toxicities differed among patients under systemic treatment or radiotherapy, since the toxicity is cumulative. 2. Asthenia is the main symptom in all cases. 3. The data of high depression redraw the need of psychological and social cares. 4. International organisms recommend applying probate quality of life tests in every oncology department, if possible EP-1143 Hypofractionated vs conventionally fractionated breast radiotherapy: Economic consequences. A.C. Ciafre 1 , J.M. Torices 1 , E. Jordá 1 , D. Dualde 1 , R. García 1 , E. Ferrer 1 1 Hospital Clinico Universitario, Oncologia Radioterapica, Valencia, Spain

+/- 0.08) & (1.53+/- 0.46) and IMRT was (1.65 +/- 0.44) & (1.51 +/- 0.26) in right and left breast. Conclusion Tomotherapy provided significant reduction in heart’s dose volume and mean lung dose. EP-1141 Acute and late toxicity of IORT during BCS followed by whole breast radiotherapy (WBI). B. Urbanski 1 , A. Roszak Andrzej 1 , K. Bratos 1 , P. Milecki 2 , A. Karczewska-Dzionk 3 , M. Litoborski 4 , S. Adamczyk 5 1 Greater Poland Cancer Centre, Radiotherapy and Gynecological Oncology, Poznan, Poland 2 Greater Poland Cancer Centre, Radiotherapy Ward I, Poznan, Poland Purpose/Objective: The aim of the study was to report acute and late toxicity of intraoperative radiotherapy (IORT) given as a boost during breast conserving surgery (BCS) followed by adjuvant whole breast radiotherapy (WBRT). Material and Methods Between 2008 and 2011 in 150 breast cancers patients treated in Greater Poland Cancer Centre. Intraoperative radiotherapy as a tumor bed boost was applied using mobile electron accelerator Mobetron 1000 (IntraOp Medical, Inc.). IORT boost (10 Gy) was followed by 50 Gy whole-breast external beam radiotherapy (EBRT). Chemotherapy, if indicated, was given before EBRT. The observation period was 1,5-5,5 years. The data was assessed by CTCAE ver. 3.0 scale 1 month and 6 months after RT. The statistical analysis was performed with Maentel-Haenszel test. Late toxicity was analyzed with LENT-SOMA scale 1 year after RT. Results 4 Candela, Candela, Warsaw, Poland 5 Intra Op, Intra Op, Sunnyvale, USA

Tab 1. Acute toxicity data set.

There was only grade I and II acute toxicity reactions. There was no statistical significance differences between (Mantel-Haenszel test) percentage of patients with acute reaction in 1 month and 6 months after RT.

Tab 2. Late toxicity data set.

The late toxicity occurred in 82 patients (55%). The main side effect of treatment was fibrosis, which has occurred in 60 patients (73.1%) from 82 in general with late radiation induced reactions. There was grade I and II predominance. Grade III occurred in 5 patients (skin Intraoperative radiotherapy is proved to be safe, well tolerable and perspective treatment procedure in breast cancer treatment. EP-1142 EORTC QLQ C-30 scores evolution in stage I-III breast cancer patients during sequential treatment retraction). Conclusion

Purpose or Objective